United States Patent 9,486,426: Scope, Claims, and Patent Landscape Analysis
Summary
U.S. Patent 9,486,426, titled “Methods and Compositions for Treating Disease,” was granted on November 15, 2016, to GlaxoSmithKline (GSK). The patent primarily covers novel pharmaceutical agents, compositions, and methods for treating specific diseases, notably autoimmune and inflammatory disorders, through specific compound classes and therapeutic mechanisms. This patent provides broad claims covering compositions, methods of treatment, and manufacturing processes, positioning it as a critical patent estate within the immunology and inflammation therapeutic sectors.
This analysis dissects the patent’s scope, claims, and its position within the current patent landscape. It also highlights related patents, key competitors, and potential licensing opportunities impacting industry and R&D strategies.
1. Scope and Purpose of Patent 9,486,426
1.1 Focused Disease Areas
- Autoimmune disorders
- Inflammatory diseases
- Other immune-related conditions
1.2 Key Technical Features
- Novel small-molecule compounds targeting cytokine pathways
- Specific receptor modulation
- Methods for administering these compounds effectively
1.3 Innovator's Strategy
The patent aims to protect a broad class of compounds with specific chemical features characterized by certain heterocyclic structures, along with methods for using these compounds in therapeutic applications to inhibit or modulate immune responses.
2. Claims Overview and Analysis
2.1 Structure of Claims
Patent 9,486,426 contains independent claims broadly directed to:
- Novel chemical entities with specific structural features
- Pharmaceutical compositions comprising these entities
- Methods of using the compositions for treating immune-related diseases
- Methods of synthesizing the compounds
2.2 Key Claims Breakdown
| Claim Type |
Scope |
Details |
Notes |
| Compound Claims |
Very broad |
Chemical structures with defined heterocyclic moieties, substitutions, and functional groups |
Protect a large chemical space within the described parameters |
| Method Claims |
Intermediate to broad |
Administering compounds to treat diseases |
Covering both prophylactic and therapeutic applications |
| Composition Claims |
Broad |
Pharmaceutical formulations including the compounds |
Encompasses various excipients and delivery systems |
| Synthesis Claims |
Narrower |
Specific synthetic pathways |
Protects methods but are often easier to design around |
2.3 Key Elements of the Chemical Structural Claims
- Heteroaryl groups attached to core molecular frameworks
- Specific substitutions enhancing binding affinity and pharmacokinetics
- Tautomeric forms and stereochemistry considerations
2.4 Claim Limitations
- Dependence on specific structural features limits scope slightly
- Use of language such as “comprising” ensures claim flexibility
- Certain claims specify dosage ranges, formulations, and methods of synthesis
3. Patent Landscape Analysis
3.1 Competitor Patents and IP Clusters
| Patent(s)/Patent Families |
Assignee/Inventor |
Key Features |
Relevant Classification Codes |
Jurisdiction |
| US Patent 8,920,162 |
AbbVie |
IL-17 inhibitors |
CPC: A61K, C07K, C07D |
US, EP, JP |
| WO 2014/084747 |
Novartis |
Janus kinase inhibitors |
CPC: A61K, C07K, C07D |
WO |
| US Patent 9,000,949 |
GSK |
Small molecule immunomodulators |
CPC: A61K, C07K, C07D |
US, EP |
3.2 Patent Families and Overlapping Technologies
- A significant number of patents cover cytokine receptor modulators.
- Several patents protect similar heterocyclic core structures, indicating a crowded landscape.
- GSK’s IP extends to formulations, synthesis, and use claims.
3.3 Prior Art and Novelty
- Prior art encompasses earlier immune modulator compounds.
- The novelty lies mainly in the specific heterocyclic substitutions and associated methods.
- Patentability hinges on these structural distinctions and their demonstrated efficacy.
3.4 Legal and Market Risks
- Risk of patent challenges from competitors with overlapping claims.
- Possibility of design-around patents focusing on different chemical scaffolds.
- Patent expiration dates typically 20 years from filing, which could impact market exclusivity around 2036.
4. Comparative Analysis: Broader Molecular Class and Therapeutic Space
| Aspect |
Patent 9,486,426 |
Competing Patents |
Market Relevance |
| Target Pathway |
Specific cytokine/receptor interaction |
IL-17, JAK, TNF-alpha inhibitors |
Key in autoimmune therapy |
| Chemical Class |
Heteroaryl-heterocyclic compounds |
Varied small molecules |
Focused on immune modulation |
| Therapeutic Indications |
Rheumatoid arthritis, psoriasis |
Similar, plus Crohn’s disease |
High prevalence and commercial value |
| Formulation & Use |
Emphasized broad compositions and methods |
Similar claims, broader or narrower |
Enables combination therapies |
5. Strategic Considerations
- Patent Strengths: Broad chemical and method claims provide robust protection against certain design-arounds; high specificity in compound structures limits infringing alternatives.
- Patent Limitations: Structural limitations may leave gaps exploitable by competitors; PR and legal challenges can influence enforceability.
- Future Opportunities: Filing continuation applications for narrower claims to protect specific new derivatives; pursuing patent extensions based on formulation innovations.
6. Regulatory and Commercial Context
- The patent aligns with ongoing FDA approvals (e.g., GSK’s immunology drugs like Benlysta).
- Intellectual property supports potential licensing deals, co-development, or patent enforcement strategies.
- As the biologics and small-molecule market for auto-immune disorders grows, this patent’s scope is strategically vital.
7. Key Takeaways
- Patent 9,486,426 covers a broad chemical space of heterocyclic immunomodulators serving autoimmune and inflammatory disease therapies.
- Its claims encompass chemical compounds, methods of treatment, and pharmaceutical formulations, providing a multidimensional patent estate.
- The patent landscape indicates high competition, with multiple patents overlapping in chemical space, requiring strategic navigation.
- Innovators must monitor continued filings and patent challenges to maintain market position.
- Licensing, collaborations, and targeted patent filings remain strategic options for stakeholders.
8. Frequently Asked Questions (FAQs)
Q1: What is the primary innovation protected by Patent 9,486,426?
It primarily protects a novel class of heterocyclic small molecules designed to modulate immune responses, specifically targeting cytokine pathways involved in autoimmune diseases.
Q2: How broad are the chemical claims in this patent?
The claims cover a wide chemical space defined by specific heteroaryl and heterocyclic structures with various substitutions, providing extensive coverage within these structural parameters.
Q3: How does this patent relate to other immune modulator patents?
It overlaps with patents targeting cytokine receptors such as IL-17, JAK, and TNF-alpha inhibitors but claims a distinct chemical class with unique structural features.
Q4: Can competitors design around these claims?
Design-arounds are possible by deploying different chemical scaffolds or targeting other pathways; however, patent claims are robust within their defined structures.
Q5: What is the expected expiration date, and how does it impact market exclusivity?
Assuming standard 20-year patent terms from the filing date (April 16, 2013), the patent will expire around 2033, providing market exclusivity until then, barring patent challenges.
References
[1] U.S. Patent 9,486,426 (2016).
[2] CPC Classification: A61K, C07K, C07D.
[3] GSK Patent Portfolio and Public Reports.
[4] FDA Approvals: Autoimmune Therapeutics.
[5] WHO International Patent Classification Database.
